🔍 Intelligence Synthesis JP/EN
Ethics · Regulation · Technology — Pharma Practice Notes

AI in Medicine News — 2026-09-29 (Tue)

Daily ReportDaily 03:10 + Evening 18:10 (JST) auto-aggregated

Source links point to the original outlet. The AI Integrated Analysis is auto-generated from the headlines below only and is not intended to add facts beyond them. Not investment advice.

Editions of the day: Daily News (Daily 03:10) / Daily News (Evening 18:10)
Daily Report06:16 JST
Source: Google News RSS / regulators and societies / ClinicalTrials.gov / YouTube  ·  Past 48 hours  ·  36 articles
AI INTEGRATED ANALYSIS2026-09-29 (Tue) — Daily Report · 06:16 JST
Movements were noticeable in the field of image diagnosis and screening support (FDA approval of breast cancer screening AI, glioblastoma recurrence prediction, and endoscopic capsule AI).

Latest news on AI and cancer treatment

Overview

Movements were noticeable in the field of image diagnosis and screening support (FDA approval of breast cancer screening AI, glioblastoma recurrence prediction, and endoscopic capsule AI). In the drug discovery field, we continue to invest in AI drug discovery platforms, such as utilizing Roche's autonomous AI drug discovery lab and raising funds for HITS from KAIST in South Korea. On the regulatory front, FDA approval for endoscopic capsule AI and Osaka University's oral cancer detection system were confirmed.

Breast cancer

- Lunit's INSIGHT MMG is being introduced for mammography interpretation in hospitals throughout the Stockholm region (PR Newswire/Korea Biomedical Review/Trend Hunter, multiple media outlets reported on the same incident). As the project is positioned as a region-wide screening program, numerical values such as accuracy and detection rate are not listed in the headline. - A research presentation by Sylvester, a cancer researcher at the University of Miami, on "Using AI in Cancer Survivorship" (target cancer types are not specified in the headline). - Boston University "AI Prognostics with Pathologist-in-the-Loop" = Research on AI prognostic prediction model with pathologist participation (target cancer types and evidence level are not listed in the heading).

lung cancer

- Roche focuses on leveraging autonomous AI drug discovery lab to develop KRAS G12C inhibitor divarasib (GenomeWeb). The development stage and clinical trial phase are not listed in the heading. *Headings related to esophageal cancer CT detection (Ynetnews) have been organized and listed under "7. Colorectal Cancer/Gastrointestinal System".

Malignant brain tumor

- A new AI tool has been reported for predicting the areas where glioblastoma is likely to recur after initial surgery (Medical Xpress). Whether the study was a single-center study or a multi-center study, or prospective/retrospective, is not stated in the heading.

Leukemia/lymphoma

No applicable information

Colon cancer/digestive organ

- AI study (Ynetnews) claims to have detected esophageal cancer from CT scans several months before diagnosis. The lead time for detection is only suggested, and the number of target patients, sensitivity specificity, and study design (preclinical/retrospective/prospective) are not listed in the heading. - FDA approves AI that presents abnormality candidates on swallowable camera (capsule endoscope) images (Stock Titan). See also “11. Regulations and Approvals” for details. - A report on the use of AI in hospitals (Newsweek) states that "if AI had not been introduced, patients would have died." Target cancer types and specificity of evidence are not listed in the heading.

Rare cancer

No applicable information

Diagnosis/Pathology/Image

- Improving the accuracy of skin cancer detection tools using AI and pointing out that the benefits are not uniform (Fast Company Middle East). Specific sensitivity, specificity, and target population are not listed in the heading. - GuideAI and vRad renew exclusive agreement for vascular AI image data (AuntMinnie). This is a business partnership related to image diagnosis infrastructure, rather than specific cancer types.

Treatment selection/drug discovery

- Roche utilizes autonomous AI drug discovery lab in development of divarasib (GenomeWeb). The stage (preclinical/clinical phase) is not stated in the heading. - Rakovina Therapeutics continues to design cancer drugs using AI (kalkine.ca). Details of the development stage are not listed in the heading. - HITS, an AI drug discovery company from KAIST, has raised approximately 18.3 billion won (equivalent to approximately 1.34 billion yen) and plans to start operating "AI Scientist" in November (finance.biggo.com). The story is about the platform stage, and there is no mention of specific drugs or clinical phases. - Efforts to build an AI infrastructure for cancer care in Somaliland (ASCO Connection). The main theme is access improvement in low resource environments. - OpenEvidence, Anthropic, and University of Pennsylvania Medical Institutions partner to expand AI access for doctors in Africa and Asia (Fierce Healthcare). The theme is not about specific cancer types, but about expanding access to clinical decision-making support AI.

Regulations/Approval

- FDA: Approved (clearance) AI that presents abnormality candidates in swallowable camera (capsule endoscopy) images. Details of item name and approval category are not listed in the heading (Stock Titan). - Osaka University's oral cancer early detection AI system receives approval (public recruitment guide). Approval entity and approval category (medical device approval under the Pharmaceutical and Medical Device Act, etc.) are not listed in the heading.

Clinical trial implementation status

No applicable information as individual data from ClinicalTrials.gov is not included in this message. No estimates will be made regarding the number of cases or registration status.

Japanese movements

- The AI system for early detection of oral cancer developed by Osaka University received approval (public recruitment guide). Details such as approval category, target patients, accuracy, etc. are not listed in the heading. *Other headlines from CHOSUNBIZ (Okuma Pharmaceutical's controlled release formulation design, Korean PE's AI infrastructure investment, TelePIX's satellite AI contract, Frontier AI resource intensive study) were excluded because they are related to South Korea and have nothing to do with cancer medicine.

Remarks from VIPs

- Khurram Khaliq Bhinder: Scholar-in-Training Award from AACR (American Association for Cancer Research), associated with research project “AI-PACED” (oncodaily.com). Details of target cancer types and research content are not listed in the heading. - Chandler Park, published a paper titled "What does AI need to do to improve oncology care?" (oncodaily.com). The title is not listed in the heading.

Excluded headlines (determined to be unrelated to cancer medical AI): Nvidia's share buyback, UltraSight (cardiac ultrasound AI), heart health monitoring AI article, Mitratech (legal AI acquisition), TelePIX satellite AI contract, Korean PE's AI infrastructure investment base, Korean government's frontier AI resource concentration consideration, Sheinelle Jones' personal article.

Latest news on AI and rare and incurable diseases

Overview

There has been a noticeable movement in the use of AI in the diagnostic field, with reports of AI applications in identifying causative gene candidates for rare neurodevelopmental diseases, classifying vasculitis, and screening for heart disease. In Japan, Kobe University reported on AI diagnosis of intractable diseases based on photographs of hands. There were no headlines regarding therapeutic drug development or systems.

Diagnosis of rare diseases

A team at Kobe University reported on their research using AI to diagnose intractable diseases from photographs of hands in a privacy-friendly manner (Sanyo Shimbun). Details such as target disease name, diagnostic accuracy, and number of target patients are unclear from the headline. Additionally, Tempus announced that it has received FDA clearance for its ECG-MR AI product, which is intended to identify undiagnosed mitral regurgitation (Business Wire). However, this is not for diagnosing rare diseases per se, but for screening for heart disease, and is still at the stage of obtaining clearance from regulatory authorities.

Gene analysis/genome

There was a report that a candidate gene for the cause of a rare neurodevelopmental disease was identified by combining genome analysis and AI (News-Medical). The research stage, number of cases, and target disease name are unclear from the headline, and it may be a case report or research stage. Codebreaker Labs announced seed funding to prepare data for genomic AI (AiThority). This is a business/financial move and does not indicate clinical results.

Development of therapeutic drugs

No applicable information

Nerve/muscular diseases

Regarding the ``rare neurodevelopmental disease'' reported in News-Medical, it is not possible to confirm from the headline that it corresponds to the list of 348 designated intractable diseases. Since there is no mention of the specific disease name that falls under the Ministry of Health, Labor and Welfare's group of neurological and muscular diseases (87 cases), it is not possible to confirm whether the disease is a designated intractable disease or not.

Immunology/Collagen disease

A study reported that AI classified rare vasculitis into three different types (ANCA Vasculitis News). The number of target patients and the stage of verification of the validity of the classification (single facility or multiple facilities, etc.) are unclear from the headline. Vasculitis is a disease that falls within the group of immune diseases designated by the Ministry of Health, Labor and Welfare as an intractable disease (Takayasu's arteritis, polyarteritis nodosa, microscopic polyangiitis, granulomatosis with polyangiitis, granulomatosis with eosinophilic polyangiitis, etc.), but since the specific name of the disease is not listed in the heading, it is not possible to confirm which designated intractable disease it corresponds to.

Rare metabolic/endocrine diseases

No applicable information

System/Patient Support

No applicable information

Japanese movements

A Kobe University team announced a privacy-friendly method for AI diagnosis of intractable diseases using hand photos (Sanyo Shimbun). The target disease and verification stage (case report or clinical trial) are unclear from the headline.

Remarks from VIPs

No applicable information

🔎 Diagnosing rare disease1
🛡️ Immune and connective tissue1
🏛️ Policy and patient support1
🇯🇵 Japan rare disease and AI1
Daily Report18:17 JST
Source: Google News RSS / regulators and societies / ClinicalTrials.gov / YouTube  ·  Past 48 hours  ·  17 articles
AI INTEGRATED ANALYSIS2026-09-29 (Tue) — Daily Report · 18:17 JST
There is movement in diagnostics (expanding the practical use of breast cancer AI screening), regulations (FDA item clearance for Tempus AI), and drug discovery (AbbVie's AI drug discovery partnership

Latest news on AI and cancer treatment

Overview

There is movement in diagnostics (expanding the practical use of breast cancer AI screening), regulations (FDA item clearance for Tempus AI), and drug discovery (AbbVie's AI drug discovery partnership). A statistical analysis of clinical trials (a review of 195 trials) was also reported, but there was no primary information showing the registration status of individual trials.

Breast cancer

It has been reported that South Korea's Lunit's breast cancer screening support AI will be used in the Stockholm area to assist in the co-reading of 250,000 mammography images a year. The target is a screening program for local residents, and quantitative results such as accuracy and detection rate are not listed in the headline. Additionally, there are reports that GEHC (GE Healthcare) and Mass General Brigham (MGB) are partnering to apply generative AI to radiation therapy (details are unknown). In Luxembourg, there was an article pointing out that the introduction of AI into hospitals is progressing without a national inventory control (central ledger), and this is cited as a governance issue for the introduction of AI, not only in the field of breast cancer.

lung cancer

No applicable information

Malignant brain tumor

No relevant information regarding clinical/research reports. In a related headline, there is a report that newscaster Sheinelle Jones said about the AI interview video that her children underwent after her husband's death, "It didn't actually happen (false)," but this is not about medical content about cancer treatment or brain tumors, but general news about AI deep fakes.

Leukemia/lymphoma

Onco'Zine publishes an article analyzing 195 clinical trials related to AI in oncology. It is unclear from the headline whether the content is specific to hematological tumors, and details such as target cancer types, phases, and registration status are not listed.

Colon cancer/digestive organ

The CDOTrends article ``The AI Is in the Scope. The Evidence Isn't.'' appears to be an article arguing that ``there is no evidence'' regarding endoscopic AI (polyp detection support, etc.), but the headline alone does not include specific test names or numerical values. Avoid making definitive statements about effectiveness, detection rate, etc.

Rare cancer

The headline that was categorized as related to adenoid cystic carcinoma was that UK DYAD raised US$10 million to expand its medical AI business and deploy it for the NHS. A direct relationship with adenoid cystic carcinoma cannot be confirmed from the headline, and the correspondence relationship is unknown.

Diagnosis/Pathology/Image

An Indian news article discusses the possibilities and challenges of "biomarkers identified by AI," but the target cancer type, measurement target, and verification stage are not mentioned in the headline. Onco'Zine's "Artificial intelligence in Oncology: Where Promise Meets Reality" is also seen as a review article that deals with the current state and challenges of AI in oncology in general.

Treatment selection/drug discovery

AbbVie has partnered with biotech company Iambic, which is preparing for an IPO, on drug discovery using AI. The stage is considered to be the "discovery" stage, and is presumed to be in the early pre-clinical stage, but there is no information on the target disease, compound, or phase in the heading.

Regulations/Approval

- Tempus AI: Reported to have obtained FDA clearance (distinguished from 510(k) clearance and approval) for ECG-MR (which appears to be a test/algorithm that combines electrocardiogram and MRI). Direct indications for cancer oncology are unclear from the headline. - South Korea's SM Entertainment has filed a criminal complaint against its artist Im Yoona for creating deepfake images. General AI regulation news unrelated to medical care and cancer treatment.

Clinical trial implementation status

Regarding the individual trial name, target cancer type, phase, and registration status from ClinicalTrials.gov, the information provided this time does not include specific trial data. We do not make assumptions about the number of cases or registration status.

Japanese movements

crisp_bio publishes an article about building a "virtual biotech". The content is about a multi-agent AI framework that operates under human instructions, and appears to be a topic related to drug discovery research infrastructure, but there is no mention of direct application to cancer treatment or clinical stages in the heading.

Remarks from VIPs

The list of important people to be tracked is blank, so there is no relevant speech information.

Note: This report is based on the headline information provided and does not reference the text of the article or primary data from ClinicalTrials.gov. In particular, there is little information on the items ``rare cancer,'' ``clinical trial implementation status,'' and ``lung cancer,'' so it is necessary to check for follow-up reports.

Latest news on AI and rare and incurable diseases

Overview

There was one case report using AI in the rare disease diagnosis field, and two cases in the genetic analysis field. There are no headings regarding therapeutic drug development or institutional aspects.

Diagnosis of rare diseases

The BBC reported that AI helped diagnose a daughter's rare disease. The specific disease name, diagnosis rate, and shortening period are not listed in the headline, and the content appears to be based on the experiences of individual families. This is a case-by-case report and does not indicate statistical effects.

Gene analysis/genome

- Medical Xpress reported that experiments using AI and fruit flies have linked the BRSK1 gene to a rare neurodevelopmental disorder. The research is at the preclinical (model organism) stage, and the verification stage in humans cannot be confirmed from the headline. Whether the disease in question falls under the list of 348 incurable diseases designated by the Ministry of Health, Labor and Welfare cannot be confirmed just from the information in the heading. The specific operational status of the platform and its track record of application to rare diseases are not mentioned in the headline, so it is not possible to judge the details.

Development of therapeutic drugs

No applicable information

Nerve/muscular diseases

Medical Xpress's BRSK1-related report mentions neurodevelopmental disorders, but this is a study on developmental disorders in children, and does not match the names of diseases in the "neuro-muscular diseases" group (87 cases, including spinal and bulbar muscular atrophy and amyotrophic lateral sclerosis). It is not possible to confirm whether it is a designated intractable disease or not.

Immunology/Collagen disease

No applicable information

Rare metabolic/endocrine diseases

No applicable information

System/Patient Support

No applicable information

Japanese movements

No applicable information

Remarks from VIPs

No applicable information

🩺 Colorectal and GI1
🔬 Rare cancers1
🖥️ Diagnosis and pathology1
💊 Treatment and drug discovery1
⚖️ Regulation and approvals2
🔎 Diagnosing rare disease1
← 2026-09-28Index2026-09-30 →
← AI in Medicine News Index